|
1
|
Weiss SW and Goldblum JR: Malignant
fibrous histiocytoma (pleomorphic undifferentiated sarcoma).
Enzinger and Weiss's Soft Tissue Tumors (5th). (Mosby, London).
1161–1182. 2008.
|
|
2
|
Marchese R, Bufo P, Carrieri G and Bove G:
Malignant fibrous histiocytoma of the kidney treated with
nephrectomy and adjuvant radiotherapy: A case report. Case Rep Med
2010. 802026:pii. 2010.
|
|
3
|
Bhavsar T, Saeed-Vafa D, Harbison S and
Inniss S: Retroperitoneal cystic lymphangioma in an adult: A case
report and review of the literature. World J Gastrointest
Pathophysiol. 1:171–176. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tarján M, Cserni G and Szabó Z: Malignant
fibrous histiocytoma of the kidney. Scand J Urol Nephrol.
35:518–520. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
O'Brien JE and Stout AP: Malignant fibrous
xanthomas Cancer. 17:1445–1455. 1964.PubMed/NCBI
|
|
6
|
Anagnostopoulos G, Sakorafas GH,
Grigoriadis K and Kostopoulos P: Malignant fibrous histiocytoma of
the liver: A case report and review of the literature. Mt Sinai J
Med. 72:50–52. 2005.PubMed/NCBI
|
|
7
|
Eilber FC, Rosen G, Eckardt J, Forscher C,
Nelson SD, Selch M, Dorey F and Eilber FR: Treatment-induced
pathologic necrosis: A predictor of local recurrence and survival
in patients receiving neoadjuvant therapy for high-grade extremity
soft tissue sarcomas. J Clin Oncol. 19:3203–3209. 2001.PubMed/NCBI
|
|
8
|
Canter RJ, Martinez SR, Tamurian RM,
Wilton M, Li CS, Ryu J, Mak W, Monsky WL and Borys D: Radiographic
and histologic response to neoadjuvant radiotherapy in patients
with soft tissue sarcoma. Ann Surg Oncol. 17:2578–2584. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shah D, Borys D, Martinez SR, Li CS,
Tamurian RM, Bold RJ, Monjazeb A and Canter R: Complete pathologic
response to neoadjuvant radiotherapy is predictive of oncological
outcome in patients with soft tissue sarcoma. Anticancer Res.
32:3911–3915. 2012.PubMed/NCBI
|
|
10
|
Hassan I, Park SZ, Donohue JH, Nagorney
DM, Kay PA, Nasciemento AG, Schleck CD and Ilstrup DM: Operative
management of primary retroperitoneal sarcomas: A reappraisal of an
institutional experience. Ann Surg. 239:244–250. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tseng WW, Wang SC, Eichler CM, Warren RS
and Nakakura EK: Complete and safe resection of challenging
retroperitoneal tumors: Anticipation of multi-organ and major
vascular resection and use of adjunct procedures. World J Surg
Oncol. 9:1432011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pezzi CM, Rawlings MS Jr, Esgro JJ,
Pollock RE and Romsdahl MM: Prognostic factors in 277 patients with
malignant fibrous histiocytoma. Cancer. 69:2098–2103. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ogura K, Goto T, Imanishi J, Shinoda Y,
Okuma T, Tsuda Y, Kobayashi H, Akiyama T, Hirata M, Yamamoto A and
Kawano H: Neoadjuvant and adjuvant chemotherapy with modified
mesna, adriamycin, ifosfamide, and dacarbazine (MAID) regimen for
adult high-grade non-small round cell soft tissue sarcomas. Int J
Clin Oncol. 18:170–176. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sherman KL, Wayne JD, Chung J, Agulnik M,
Attar S, Hayes JP, Laskin WB, Peabody TD, Bentrem DJ, Pollock RE
and Bilimoria KY: Assessment of multimodality therapy use for
extremity sarcoma in the United States. J Surg Oncol. 109:395–404.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wendtner CM, Abdel-Rahman S, Krych M,
Baumert J, Lindner LH, Baur A, Hiddeman W and Issels RD: Response
to neoadjuvant chemotherapy combined with regional hyperthermia
predicts long-term survival for adult patients with retroperitoneal
and visceral high-risk soft tissue sarcomas. J Clinical Oncol.
20:3156–3164. 2002. View Article : Google Scholar
|
|
16
|
Mohagheghi MA, Sadighi S, Raafat J,
Mosavi-Jarrahi AR, Seddigh Z and Ghaemi A: Neoadjuvant chemotherapy
with ifosfamide, cisplatin, adriamycin and mitomycin (IMAP) for
high risk adult soft tissue sarcomas. Acta Med Iran. 47:133–138.
2009.
|
|
17
|
Gilbeau L, Kantor G, Stoeckle E, Lagarde
P, Thomas L, Kind M, Richaud P, Coindre JM, Bonichon F and Bui BN:
Surgical resection and radiotherapy for primary retroperitoneal
soft tissue sarcoma. Radiother Oncol. 65:137–143. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pervaiz N, Colterjohn N, Farrokhyar F,
Tozer R, Figueredo A and Ghert M: A systematic meta-analysis of
randomized controlled trials of adjuvant chemotherapy for localized
resectable soft-tissue sarcoma. Cancer. 113:573–581. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mullen JT, Kobayashi W, Wang JJ, Harmon
DC, Choy E, Hornicek FJ, Rosenberg AE, Chen YL, Spiro IJ and
DeLaney TF: Long-term follow-up of patients treated with
neoadjuvant chemotherapy and radiotherapy for large, extremity soft
tissue sarcomas. Cancer. 118:3758–3765. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Van Glabbeke M, van Oosterom AT,
Oosterhuis JW, Mouridsen H, Crowther D, Somers R, Verweij J,
Santoro A, Buesa J and Tursz T: Prognostic factors for the outcome
of chemotherapy in advanced soft tissue sarcoma: An analysis of
2,185 patients treated with anthracycline-containing first-line
regimens-a european organization for research and treatment of
cancer soft tissue and bone sarcoma group study. J Clin Oncol.
17:150–157. 1999.PubMed/NCBI
|
|
21
|
Bui-Nguyen B, Ray-Coquard I, Chevreau C,
Penel N, Bay JO, Coindre JM, Cupissol D, Italiano A, Bonichon F,
Lotz JP, et al: High-dose chemotherapy consolidation for
chemosensitive advanced soft tissue sarcoma patients: An
open-label, randomized controlled trial. Ann Oncol. 23:777–784.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fayette J, Penel N, Chevreau C, Blay JY,
Cupissol D, Thyss A, Guillemet C, Rios M, Rolland F, Fargeot P, et
al: Phase III trial of standard versus dose-intensified
doxorubicin, ifosfamide and dacarbazine (MAID) in the first-line
treatment of metastatic and locally advanced soft tissue sarcoma.
Invest New Drugs. 27:482–489. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kasper B, Ouali M, van Glabbeke M, Blay
JY, Bramwell VH, Woll PJ, Hohenberger P and Schöffski P: Prognostic
factors in adolescents and young adults (AYA) with high risk soft
tissue sarcoma (STS) treated by adjuvant chemotherapy: A study
based on pooled European organisation for research and treatment of
cancer (EORTC) clinical trials 62771 and 62931. Eur J Cancer.
49:449–456. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Elias A, Ryan L, Sulkes A, Collins J,
Aisner J and Antman KH: Response to mesna, doxorubicin, ifosfamide,
and dacarbazine in 108 patients with metastatic or unresectable
sarcoma and no prior chemotherapy. J Clin Oncol. 7:1208–1216.
1989.PubMed/NCBI
|
|
25
|
Salgado Rand and vanMarck E: Soft tissue
tumours: The surgical pathologist's perspective. Imaging of Soft
Tissue Tumors. De Schepper AM, Vanhoemacker F, Gielen J and Parizel
PM: (3rd). Springer. (Berlin, Germany). 107–116. 2006. View Article : Google Scholar
|
|
26
|
Spurrell EL, Fisher C, Thomas JM and
Judson IR: Prognostic factors in advanced synovial sarcoma: An
analysis of 104 patients treated at the Royal Marsden Hospital. Ann
Oncol. 16:437–444. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Karavasilis V, Seddon BM, Ashley S,
Al-Muderis O, Fisher C and Judson I: Significant clinical benefit
of first-line palliative chemotherapy in advanced soft-tissue
sarcoma: Retrospective analysis and identification of prognostic
factors in 488 patients. Cancer. 112:1585–1591. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jones RL, Fisher C, Al-Muderis O and
Judson IR: Differential sensitivity of liposarcoma subtypes to
chemotherapy. Eur J Cancer. 41:2853–2860. 2005. View Article : Google Scholar : PubMed/NCBI
|
